Sam Byrnes

Last month, I was sitting in a hotel lobby (actually the Bar) in Amsterdam after attending the International Plasma Protein Conference. I started talking with a fellow attendee who is a Patient Advocate for the rare diseases, Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (don’t lose me, I... Show More

Thanks for your comment Rodney. It is an interesting one. Given the supply shortage I wonder how much Share Shire (now Takeda) could take, even if they have a better drug profile. You are right, It was on 9x PE, but had some chunky debt and a lot of Hemophilia earnings still to lose (a few billion revenue, which is all margin, making the future PE a lot higher). It was cheap though and Takeda certainly agreed with you. Also wonder if the market is looking at more than just global plasma comps for CSL?

On Why do Australians pay crazy multiples for CSL? -